{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.63","value":"2.7"},{"groupId":"OG001","spread":"0.89","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.66","value":"2.5"},{"groupId":"OG001","spread":"1.25","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 56"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.51","value":"2.2"},{"groupId":"OG001","spread":"0.93","value":"2.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 78"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.43","value":"2.0"},{"groupId":"OG001","spread":"0.79","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Change at Day 100"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"description":"PGIC was a single item to assess the participant's perception in change of their overall health status using a 7-point verbal rating scale ranging from 1(a lot better now) to 7 (a lot verse now), where 1: a lot better now; 2: moderately better now; 3: a little better now; 4: neither better nor worse; 5: a little worse now; 6: moderately worse now; 7: a lot worse now. Higher score indicated worse health status.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG000","title":"Phase 2 (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received RP2D dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG001","title":"Phase 2 (Japan Population)"}],"paramType":"MEAN","populationDescription":"mITT analysis set included all participants who received a JNJ-68284528 infusion at the targeted RP2D dose level. Here, N (number of participants analyzed) signifies participants who were evaluable for this outcome measure and \"n\" (number analyzed) signifies those participants who were evaluable at specified time points.","reportingStatus":"POSTED","timeFrame":"Days 28, 56, 78, 100","title":"Phase 2: Patient Global Impression of Change (PGIC) Score at Days 28, 56, 78, 100","type":"SECONDARY","unitOfMeasure":"Score on a scale"}